Maze Therapeutics, Inc. (MAZE) Insider Ownership

According to recent filings covering the 90 days ending February 19, 2026, the three most significant insider holders at Maze Therapeutics are TenPercentOwner Rock Ventures Iv, L.P. Third (5.42Mn shares), Director Jonathan E Lim (307.96K shares), Director Charles J Homcy (38.53K shares).

• A detailed ownership breakdown for Maze Therapeutics is not available at this time.
• At February 19, 2026, insider ownership concentration at Maze Therapeutics equals 12.71% of the company's equity base, encompassing roughly 5.79Mn shares from 45.59Mn total outstanding.
• Throughout the 90-day span concluding February 19, 2026, Maze Therapeutics's insider stake decreased 21.67%, as collective insider positions declining from 7.40Mn shares to 5.79Mn shares.
• Throughout the 90-day period ending February 19, 2026, President And R&D & Cmo Harold Bernstein led insider buying activity at Maze Therapeutics, acquiring 90.00K shares.
• As of February 19, 2026, President And R&D & Cmo Harold Bernstein recorded the highest insider sale volume at Maze Therapeutics, offloading 90.00K shares during the preceding 90-day window.